SCIENTIFIC HUB

Araştırmanın izini sürün.

SCIENTIFIC LITERATURE · MED

Serebrospinal Sıvı Nörofilament Işık Zincirinin Alfa-Synükleinopatiler için İşaretleyici Olarak Tespiti.

Detection of Cerebrospinal Fluid Neurofilament Light Chain as a Marker for Alpha-Synucleinopathies.

Makine çevirisi · Editoryal inceleme bekliyor

Front Aging Neurosci · 2021-09-22

DOI: 10.3389/fnagi.2021.717930PMID: 34630068

Open accessbrief-report; Journal ArticleKaynağa git ↗

Araştırma özeti

Aşağıdaki metin kaynak makalenin lisansı doğrulanmış orijinal özetidir. cc by

Alpha-synucleinopathies, such as Parkinson's disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA), are a class of neurodegenerative diseases. A diagnosis may be challenging because clinical symptoms partially overlap, and there is currently no reliable diagnostic test available. Therefore, we aimed to identify a suitable marker protein in cerebrospinal fluid (CSF) to distinguish either between different types of alpha-synucleinopathies or between alpha-synucleinopathies and controls. In this study, the regulation of different marker protein candidates, such as alpha-synuclein (a-Syn), neurofilament light chain (NfL), glial fibrillary acidic protein (GFAP), and total tau (tau) in different types of alpha-synucleinopathies, had been analyzed by using an ultrasensitive test system called single-molecule array (SIMOA). Interestingly, we observed that CSF-NfL was significantly elevated in patients with DLB and MSA compared to patients with PD or control donors. To differentiate between groups, receiver operating characteristic (ROC) curve analysis resulted in a very good diagnostic accuracy as indicated by the area under the curve (AUC) values of 0.87-0.92 for CSF-NfL. Furthermore, we observed that GFAP and tau were slightly increased either in DLB or MSA, while a-Syn levels remained unregulated. Our study suggests NfL as a promising marker to discriminate between different types of alpha-synucleinopathies or between DLB/MSA and controls.

Bilimsel değerlendirme

01

Araştırma sorusu

Sorunun kapsamı orijinal çalışma üzerinden değerlendirilir.

02

Yöntem ve örneklem

Çalışma tasarımı ve örneklem için kaynak makaleyi kontrol edin.

03

Temel bulgular

Bu kayıt için editoryal olarak onaylanmış bulgu özeti henüz yayımlanmadı.

04

Sınırlılıklar

Sonuçların genellenebilirliği, yanlılık ve klinik anlamı ayrıca incelenmelidir.

Bibliyografik veriden yöntem, örneklem veya klinik sonuç çıkarımı yapılmaz.